Posted by Michael Wonder on 24 Mar 2020
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
23 March 2020 - Despite its unavailability in Canada, patients legally imported the drug under provisions of the Canadian Food and Drugs Act and then had to find ways to receive intravenous administration.
Edavarone was approved by Health Canada in October 2018, and its manufacturer established a compassionate use program to provide no-cost edaravone access to 210 Canadian patients through provincial Special Access Programmes, which created an ethical dilemma for clinics.
